Literature DB >> 29562407

[Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer].

.   

Abstract

Colorectal cancer is one of the most common malignant tumors in China. In 2012 one million thirty six thousand cases of colorectal cancer were diagnosed all over the world, two hundred fifty three thousand cases were diagnosed in China (accounted for 18.6%). China has the largest number of new cases of colorectal cancer in the world. Colorectal cancer has becoming a serious threat of Chinese residents' health. In 2010, the National Ministry of Health organized colorectal cancer expertise of the Chinese Medical Association to write the "Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer" (2010edition), and publish it publicly. In recent years, the National Health and Family Planning Commission has organized experts to revised the protocol 2 times: the first time in 2015, the second time in 2017. The revised part of "Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer" (2017 edition) involves new progress in the field of imaging examination, pathological evaluation, surgery, chemotherpy and radiotherapy. The 2017 edition of the protocol not only referred to the contents of the international guidelines, but also combined with the specific national conditions and clinical practice in China, and also included many evidence-based clinical data in China recently. The 2017 edition of the protocol would further promote the standardization of diagnosis and treatment of colorectal cancer in China, improve the survival and prognosis of patients, and benefit millions of patients with colorectal cancer and their families.

Entities:  

Keywords:  Colorectal neoplasms; Guidebooks

Mesh:

Year:  2018        PMID: 29562407     DOI: 10.3760/cma.j.issn.0529-5815.2018.E001

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  2 in total

Review 1.  Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition).

Authors:  Jian Li; Ying Yuan; Fan Yang; Yi Wang; Xu Zhu; Zhenghang Wang; Shu Zheng; Desen Wan; Jie He; Jianping Wang; Yi Ba; Chunmei Bai; Li Bai; Wei Bai; Feng Bi; Kaican Cai; Muyan Cai; Sanjun Cai; Gong Chen; Keneng Chen; Lin Chen; Pengju Chen; Pan Chi; Guanghai Dai; Yanhong Deng; Kefeng Ding; Qingxia Fan; Weijia Fang; Xuedong Fang; Fengyi Feng; Chuangang Fu; Qihan Fu; Yanhong Gu; Yulong He; Baoqing Jia; Kewei Jiang; Maode Lai; Ping Lan; Enxiao Li; Dechuan Li; Jin Li; Leping Li; Ming Li; Shaolei Li; Yexiong Li; Yongheng Li; Zhongwu Li; Xiaobo Liang; Zhiyong Liang; Feng Lin; Guole Lin; Hongjun Liu; Jianzhong Liu; Tianshu Liu; Yunpeng Liu; Hongming Pan; Zhizhong Pan; Haiping Pei; Meng Qiu; Xiujuan Qu; Li Ren; Zhanlong Shen; Weiqi Sheng; Chun Song; Lijie Song; Jianguo Sun; Lingyu Sun; Yingshi Sun; Yuan Tang; Min Tao; Chang Wang; Haijiang Wang; Jun Wang; Shubin Wang; Xicheng Wang; Xishan Wang; Ziqiang Wang; Aiwen Wu; Nan Wu; Lijian Xia; Yi Xiao; Baocai Xing; Bin Xiong; Jianmin Xu; Jianming Xu; Nong Xu; Ruihua Xu; Zhongfa Xu; Yue Yang; Hongwei Yao; Yingjiang Ye; Yonghua Yu; Yueming Yu; Jinbo Yue; Jingdong Zhang; Jun Zhang; Suzhan Zhang; Wei Zhang; Yanqiao Zhang; Zhen Zhang; Zhongtao Zhang; Lin Zhao; Ren Zhao; Fuxiang Zhou; Jian Zhou; Jing Jin; Jin Gu; Lin Shen
Journal:  J Hematol Oncol       Date:  2019-02-14       Impact factor: 17.388

2.  Tenacissoside H Induces Apoptosis and Inhibits Migration of Colon Cancer Cells by Downregulating Expression of GOLPH3 Gene.

Authors:  Zhong-Shi Hong; Hai-Bin Zhuang; Cheng-Zhi Qiu; Ze-Sheng Shi; Chun-Xiao Wang; Zhi-Chuan Chen; Jian-Peng Pan
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-07       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.